USA flag logo/image

An Official Website of the United States Government

A Novel High-Efficiency Transfection Technology

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43GM100587
Solicitation Year:
2012
Solicitation Topic Code:
NIGMS
Solicitation Number:
PA11-096
Small Business Information
LAVAX
1265 N WELLINGTON DR PALATINE, IL 60067-
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: A Novel High-Efficiency Transfection Technology
Agency: HHS
Contract: 1R43GM100587-01A1
Award Amount: $254,578.00
 

Abstract:

DESCRIPTION (provided by applicant): Transfection is the process of introducing nucleic acids into eukaryotic cells. Not only is it a key step in medical treatment involving gene therapy and RNA interference, but it is also a powerful tool for studying gene function and protein expression in a cell. Many commercial products for transfection have been available on the market, but none has achieved perfect (100%) transfection. For certain types of treatment, such as cancer gene knockdown with RNA interference, perfect transfection is highly desirable. We have developed a novel technology that has repeatedly achieved perfect transfections with varying cell types in a laboratory setting. The long-term goal of this project is to develop commercial products for delivering various biomolecules into mammalian cells with perfect transfection efficiency. To this end, we will pursue three specific aims: (i) optimize transfection conditions; (ii) standardize transfection reagents; and (iii) develop prototype commercialtransfection kits and confirm the product quality. Upon completion of these studies, we will have developed prototype commercial kits that can achieve perfect transfection for multiple cell types with a reasonable shelf life and stability. The successful development of these products will greatly benefit biomedical research in many areas. PUBLIC HEALTH RELEVANCE: We propose to develop commercial products based on a novel technology that can deliver genes and other biomolecules into cells with perfect efficiency, which can greatly benefit biomedical research.

Principal Investigator:

Renjie Chang
224-578-2859
renjiechang@gmail.com

Business Contact:

Renjie Chang
224-578-2859
renjiechang@gmail.com
Small Business Information at Submission:

LAVAX
1265 N WELLINGTON DR PALATINE, IL 60067-

EIN/Tax ID: 127019945
DUNS: N/A
Number of Employees: N/A
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No